WO2011069283A1 - Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral - Google Patents
Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral Download PDFInfo
- Publication number
- WO2011069283A1 WO2011069283A1 PCT/CN2009/075360 CN2009075360W WO2011069283A1 WO 2011069283 A1 WO2011069283 A1 WO 2011069283A1 CN 2009075360 W CN2009075360 W CN 2009075360W WO 2011069283 A1 WO2011069283 A1 WO 2011069283A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brain
- contrast agent
- cerebral
- ecs
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 210000003722 extracellular fluid Anatomy 0.000 title claims abstract description 23
- 210000001723 extracellular space Anatomy 0.000 title claims abstract description 20
- 230000002490 cerebral effect Effects 0.000 title abstract description 11
- 210000004556 brain Anatomy 0.000 claims abstract description 130
- 239000002872 contrast media Substances 0.000 claims abstract description 77
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract description 57
- 230000008859 change Effects 0.000 claims abstract description 13
- 238000009826 distribution Methods 0.000 claims abstract description 6
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims abstract description 4
- 238000003384 imaging method Methods 0.000 claims description 19
- 239000000700 radioactive tracer Substances 0.000 claims description 17
- 230000005291 magnetic effect Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 abstract description 42
- 210000003484 anatomy Anatomy 0.000 abstract description 6
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 210000001159 caudate nucleus Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004885 white matter Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000002616 MRI contrast agent Substances 0.000 description 4
- 238000002597 diffusion-weighted imaging Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 238000012634 optical imaging Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 238000012307 MRI technique Methods 0.000 description 2
- 101000572948 Rattus norvegicus POU domain, class 3, transcription factor 3 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 101000738964 Rattus norvegicus POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical group [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229940005649 gadopentetate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000501 nonneurotoxic Toxicity 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- -1 potassium ions Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
- A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/057—General characteristics of the apparatus combined with other kinds of therapy with magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
Definitions
- Figure 3 is a fitting curve of contrast agent concentration and MRI signal intensity obtained under different experimental conditions from Figure 1;
- Figure 7 (a) to Figure 7 (e) are MRI images of the rat brain ECS at different times after introduction of the contrast agent measured by the measuring device shown in Figure 4;
- C ed is the concentration of the contrast agent Gd-DTPA at this position, in mM
- Figure 3 is the fitting curve corresponding to Experiment 1 in Table 1, that is, the measurement results when the magnetic field strength is 1.5T, the imaging sequence is FLASH 2D, the contrast agent is Gd-DTPA, and the concentration interval is 0-1.2 mM. Based on the fitted curve, the value is 337.434 and the s value is 184.344.
- Concentration gradient VC indicates the concentration gradient due to liquid flow. VC is used to describe the influence of bulk flow. If the distance between two measurement points is close, the influence of the agglomeration between them can be neglected.
- the MRI imaging method adopted by the present invention it is possible to select a specific region (for example, a resolution of 0.1 X 0.1 X 0.1 cm 3 ) for analysis in one imaging, and to display a contrast agent in the whole brain range.
- the diffusion also provides information on the three-dimensional anatomy of the brain.
- the measurement object may be a living animal, and does not necessarily have to be an ex vivo tissue.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- High Energy & Nuclear Physics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Signal Processing (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
La présente invention concerne un procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral (ISF) et l'espace extracellulaire cérébral (ECS). Il s'agit d'un procédé pour mesurer des paramètres physiologiques tels que la diffusion, le débit et l'élimination, etc. de matériaux entre l'ISF cérébral et l'ECS cérébral. Le procédé comprend les étapes de : placement du cerveau du sujet dans le dispositif d'imagerie par résonance magnétique, administration d'un agent de contraste d'imagerie par résonance magnétique dans l'ISF cérébral d'un sujet, puis mesure de l'intensité de signal de l'agent de contraste dans l'image IRM, et en fonction de l'intensité de signal, détermination de la distribution de l'agent de contraste dans la partie correspondante, et de la concentration et du taux de changement de concentration de l'agent de contraste dans chaque région du cerveau. L'invention peut mesurer les performances en ce qui concerne la diffusion, le débit et l'élimination de l'ISF dans l'ECS cérébral par le changement de signal d'image de l'agent de contraste sur le dispositif IRM, et peut également mesurer les cibles de l'ISF cérébral et de l'ECS cérébral telles que la structure anatomique et les paramètres physiologiques, etc.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2009/075360 WO2011069283A1 (fr) | 2009-12-07 | 2009-12-07 | Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral |
| CN200980126605.2A CN102238908B (zh) | 2009-12-07 | 2009-12-07 | 脑组织间液与脑细胞外间隙的生理参数测量方法 |
| US13/511,681 US20120238865A1 (en) | 2009-12-07 | 2009-12-07 | Method for Measuring the Physiological Parameters of Brain Interstitial Fluid and Brain Extracellular Space |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2009/075360 WO2011069283A1 (fr) | 2009-12-07 | 2009-12-07 | Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011069283A1 true WO2011069283A1 (fr) | 2011-06-16 |
Family
ID=44145080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2009/075360 WO2011069283A1 (fr) | 2009-12-07 | 2009-12-07 | Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20120238865A1 (fr) |
| CN (1) | CN102238908B (fr) |
| WO (1) | WO2011069283A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2803317A4 (fr) * | 2012-01-13 | 2017-08-30 | Peking University Third Hospital | Procédé pour la mesure de paramètres de diffusion d'un traceur dans un espace tissulaire et un espace extracellulaire d'organes vivants |
| WO2018174721A2 (fr) | 2017-03-23 | 2018-09-27 | Brainwidesolutions As | Fluides indicateurs, systèmes et procédés pour évaluer le mouvement de substances dans, vers ou depuis un compartiment de liquide céphalorachidien, de cerveau ou de moelle épinière d'une cavité cranio-spinale d'un être humain |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083548A1 (fr) | 2010-12-23 | 2012-06-28 | Han Hongbin | Procédé d'administration de citicoline pour traiter un accident vasculaire cérébral |
| CN104274176B (zh) * | 2013-07-11 | 2018-10-30 | 韩鸿宾 | 脑组织微观结构的无创测量方法 |
| CN112741706B (zh) * | 2019-10-29 | 2024-05-14 | 北京大学第三医院（北京大学第三临床医学院） | 制备扩散源的方法和装置及测量实体组织的细胞外间隙的生理参数的方法 |
| US20230022136A1 (en) * | 2020-08-21 | 2023-01-26 | Jinghua Wang | Diffusivity contrast agents for medical imaging |
| WO2023108478A1 (fr) * | 2021-12-15 | 2023-06-22 | 北京大学第三医院（北京大学第三临床医学院） | Méthode physique et appareil de régulation du transport moléculaire dans un espace extracellulaire cérébral |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457744A (zh) * | 2002-05-17 | 2003-11-26 | 西门子公司 | 空间分辨显示脑功能活动变化方法及核自旋断层造影设备 |
| CN1689510A (zh) * | 2004-04-19 | 2005-11-02 | 中国科学院自动化研究所 | 磁共振灌注成像的数字化方法 |
| US7419654B2 (en) * | 2004-10-08 | 2008-09-02 | Mrinal K. Dewanjee | Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents |
| WO2008139480A2 (fr) * | 2007-05-16 | 2008-11-20 | Yeda Research And Development Co. Ltd. | Evaluation d'une rupture de la barrière hématoencéphalique |
| CN101332088A (zh) * | 2008-07-21 | 2008-12-31 | 深圳先进技术研究院 | 一种获取脑部特征参数的方法、系统及溶栓决策系统及方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767196B2 (en) * | 2005-11-21 | 2010-08-03 | The University Of Hong Kong | Optimized relaxivity and specificity hepatobiliary MRI contrast agent |
| US20080081980A1 (en) * | 2006-09-18 | 2008-04-03 | Michael Maschke | Apparatus and process for stroke examination and treatment using a C-arch X-ray system |
| EP1992957B1 (fr) * | 2007-05-16 | 2013-01-02 | BrainLAB AG | Procédé pour l'estimation de paramètres physiologiques définissant l'ýdème induit lors de la perfusion d'un fluide à partir d'un cathéter placé dans le parenchyme |
-
2009
- 2009-12-07 US US13/511,681 patent/US20120238865A1/en not_active Abandoned
- 2009-12-07 WO PCT/CN2009/075360 patent/WO2011069283A1/fr active Application Filing
- 2009-12-07 CN CN200980126605.2A patent/CN102238908B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457744A (zh) * | 2002-05-17 | 2003-11-26 | 西门子公司 | 空间分辨显示脑功能活动变化方法及核自旋断层造影设备 |
| CN1689510A (zh) * | 2004-04-19 | 2005-11-02 | 中国科学院自动化研究所 | 磁共振灌注成像的数字化方法 |
| US7419654B2 (en) * | 2004-10-08 | 2008-09-02 | Mrinal K. Dewanjee | Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents |
| WO2008139480A2 (fr) * | 2007-05-16 | 2008-11-20 | Yeda Research And Development Co. Ltd. | Evaluation d'une rupture de la barrière hématoencéphalique |
| CN101332088A (zh) * | 2008-07-21 | 2008-12-31 | 深圳先进技术研究院 | 一种获取脑部特征参数的方法、系统及溶栓决策系统及方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2803317A4 (fr) * | 2012-01-13 | 2017-08-30 | Peking University Third Hospital | Procédé pour la mesure de paramètres de diffusion d'un traceur dans un espace tissulaire et un espace extracellulaire d'organes vivants |
| WO2018174721A2 (fr) | 2017-03-23 | 2018-09-27 | Brainwidesolutions As | Fluides indicateurs, systèmes et procédés pour évaluer le mouvement de substances dans, vers ou depuis un compartiment de liquide céphalorachidien, de cerveau ou de moelle épinière d'une cavité cranio-spinale d'un être humain |
| US11272841B2 (en) | 2017-03-23 | 2022-03-15 | Brainwidesolutions As | Indicator fluids, systems, and methods for assessing movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity of a human |
| US12016651B2 (en) | 2017-03-23 | 2024-06-25 | Brainwidesolutions As | Indicator fluids, systems, and methods for assessing movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity of a human |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102238908A (zh) | 2011-11-09 |
| US20120238865A1 (en) | 2012-09-20 |
| CN102238908B (zh) | 2013-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011069283A1 (fr) | Procédé pour mesurer des paramètres physiologiques dans le fluide interstitiel cérébral et l'espace extracellulaire cérébral | |
| US8686727B2 (en) | CEST MRI methods for imaging of metabolites and the use of same as biomarkers | |
| Latour et al. | Spreading waves of decreased diffusion coefficient lifter cortical stimulation in the rat brain | |
| DE69920425T2 (de) | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter | |
| Takahashi et al. | Development of cerebral fiber pathways in cats revealed by diffusion spectrum imaging | |
| US9157976B2 (en) | CEST MRI methods for imaging glutaminolysis in cancer | |
| US8565854B2 (en) | Method and system for diffusion magnetic resonance imaging | |
| Colvin et al. | New insights into tumor microstructure using temporal diffusion spectroscopy | |
| Han et al. | An in vivo study with an MRI tracer method reveals the biophysical properties of interstitial fluid in the rat brain | |
| Najafi et al. | Longitudinal measurements of syrinx size in a rat model of posttraumatic syringomyelia | |
| JP2005503221A (ja) | 偏極１２９ｘｅを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および／または器官もしくは系の機能のインビボ評価のための方法 | |
| Minhas et al. | Measuring kidney perfusion, pH, and renal clearance consecutively using MRI and multispectral optoacoustic tomography | |
| Marty et al. | Hindered diffusion of MRI contrast agents in rat brain extracellular micro‐environment assessed by acquisition of dynamic T1 and T2 maps | |
| Tirosh et al. | Neuronal activity significantly reduces water displacement: DWI of a vital rat spinal cord with no hemodynamic effect | |
| Kim et al. | Magneto-acoustic protein nanostructures for non-invasive imaging of tissue mechanics in vivo | |
| Blanchard et al. | MR-pathological comparison in F98-Fischer glioma model using a human gantry | |
| Porcari et al. | Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T | |
| Sharma | Gadolinium toxicity: epidermis thickness measurement by magnetic resonance imaging at 500 MHz | |
| WO2013104132A1 (fr) | Procédé pour la mesure de paramètres de diffusion d'un traceur dans un espace tissulaire et un espace extracellulaire d'organes vivants | |
| Hu et al. | Measurement of BAT activity by targeted molecular magnetic resonance imaging | |
| Ozarslan et al. | Characterization of anomalous diffusion from MR signal may be a new probe to tissue microstructure | |
| Liu et al. | In Vivo MR Imaging of the Flow of the Brain Interstitial Fluid | |
| Min et al. | Detection of changes in membrane potential by magnetic resonance imaging | |
| Leung et al. | Multimodality pH imaging in a mouse dorsal skin fold window chamber model | |
| EP3639741A1 (fr) | Procédé d'évaluation destiné à effectuer une différenciation entre un muscle lent et un muscle rapide en utilisant l'irm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200980126605.2 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09851963 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13511681 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09851963 Country of ref document: EP Kind code of ref document: A1 |